[Current insights in malignant pleural mesothelioma].
Faced with the rising incidence of malignant pleural mesothelioma (MPM), the medical community is now busy to improve the care for this pathology. Although there is still no unanimously recognized therapy for MPM, long survival has been observed for some patients treated with associated therapies (surgery + radiotherapy + chemotherapy). However, the detection and the aggressive care of early stages MPM must be justified by a demonstrated survival improvement with conservation of a good quality of life. This article tries to summarize current insights concerning epidemiology, diagnosis and treatment of MPM. At now, more questions than responses exist concerning the care of this severe prognosis disease.
Bard
Martin
M
Département de médecine, Institut Gustave-Roussy, 39, rue Camille-Desmoulins, 94805 Villejuif Cedex.
Debrosse
Denis
D
Caliandro
Raffaele
R
Girard
Philippe
P
Grunenwald
Dominique
D
Ruffié
Pierre
P
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001691:Biological Therapy / Q000379:methods; D006801:Humans; D007167:Immunotherapy; D008168:Lung / Q000601:surgery; D008654:Mesothelioma / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D009367:Neoplasm Staging / Q000379:methods; D010994:Pleura / Q000601:surgery; D010997:Pleural Neoplasms / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*
D000970:Antineoplastic Agents